Research programme: eye disorder gene therapies - Applied Genetic Technologies Corporation/Biogen

Drug Profile

Research programme: eye disorder gene therapies - Applied Genetic Technologies Corporation/Biogen

Alternative Names: Adeno-associated virus vector expressing human RPGR-ORF15 gene; Age-related macular degeneration gene therapy- Applied Genetic Technologies Corporation; AGTC 501; rAAV2tYF-GRK1-RPGR; X-linked retinitis pigmentosa gene therapy - Applied Genetic Technologies Corporation; XLRP gene therapy - Applied Genetic Technologies Corporation

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Retinitis pigmentosa

Most Recent Events

  • 13 Sep 2017 AGTC plans a phase I/II trial for Retinitis pigmentosa (X-linked; In children, In adolescents, In adults, In the elderly) in USA in January 2018 (NCT03316560)
  • 10 Aug 2017 Applied Genetic Technologies Corporation files an IND application with the FDA in USA for Retinitis pigmentosa
  • 10 Aug 2017 Applied Genetic Technologies Corporation plans a phase I/II trial for Retinitis pigmentosa in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top